Ralph Weichselbaum to Drug Administration Schedule
This is a "connection" page, showing publications Ralph Weichselbaum has written about Drug Administration Schedule.
Connection Strength
0.274
-
Paclitaxel, 5-fluorouracil, hydroxyurea, and concomitant radiation therapy for poor-prognosis head and neck cancer. Semin Radiat Oncol. 1999 Apr; 9(2 Suppl 1):70-6.
Score: 0.033
-
Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res. 1998 Dec 15; 58(24):5686-9.
Score: 0.032
-
Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol. 1994 Nov; 12(11):2351-9.
Score: 0.024
-
Neoadjuvant PFL augmented by methotrexate and piritrexim followed by concomitant chemoradiotherapy for advanced head and neck cancer: a feasible and active approach. Ann Oncol. 1992 Jan; 3(1):79-81.
Score: 0.020
-
5-Fluorouracil, leucovorin, hydroxyurea, and escalating doses of continuous-infusion cisplatin with concomitant radiotherapy: a clinical and pharmacologic study. Cancer Chemother Pharmacol. 1992; 29(3):178-84.
Score: 0.020
-
Survival and analysis of failure following hydroxyurea, 5-fluorouracil and concomitant radiation therapy in poor prognosis head and neck cancer. Am J Clin Oncol. 1991 Oct; 14(5):419-26.
Score: 0.019
-
Cisplatin and fluorouracil chemotherapy does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J Clin Oncol. 1991 Aug; 9(8):1376-84.
Score: 0.019
-
A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. Cancer. 1990 Jul 15; 66(2):206-13.
Score: 0.018
-
Combined modality treatment of head and neck cancer with cisplatin, bleomycin, methotrexate-leucovorin chemotherapy. Cancer. 1985 May 01; 55(9 Suppl):2149-55.
Score: 0.012
-
Multicenter randomized Phase II study of paclitaxel (1-hour infusion), fluorouracil, hydroxyurea, and concomitant twice daily radiation with or without erythropoietin for advanced head and neck cancer. Clin Cancer Res. 2003 May; 9(5):1689-97.
Score: 0.011
-
Clinical protocol. An open-label, phase I, dose-escalation study of tumor necrosis factor-alpha (TNFerade Biologic) gene transfer with radiation therapy for locally advanced, recurrent, or metastatic solid tumors. Hum Gene Ther. 2001 Jun 10; 12(9):1109-31.
Score: 0.009
-
Induction chemotherapy followed by concomitant chemoradiotherapy in the treatment of locoregionally advanced oropharyngeal cancer. Cancer J. 2001 Mar-Apr; 7(2):140-8.
Score: 0.009
-
Initial adjuvant weekly high dose methotrexate with leucovorin rescue in advanced squamous carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 1978 Jul-Aug; 4(7-8):671-4.
Score: 0.008
-
Initial adjuvant therapy in advanced squamous cell carcinoma of the head and neck employing weekly high dose methotrexate with leucovorin rescue. Laryngoscope. 1978 Apr; 88(4):632-8.
Score: 0.008
-
Continuous infusion paclitaxel, 5-fluorouracil, and hydroxyurea with concomitant radiotherapy in patients with advanced or recurrent head and neck cancer. Semin Oncol. 1997 Feb; 24(1 Suppl 2):S2-68-S2-71.
Score: 0.007
-
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol. 1993 Feb; 11(2):360-8.
Score: 0.005
-
Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. Cancer. 1989 Mar 15; 63(6 Suppl):1048-53.
Score: 0.004
-
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. Cancer. 1989 Jan 01; 63(1):30-6.
Score: 0.004
-
Sequential administration of methotrexate, cisplatin, and 5-fluorouracil in multimodal therapy for locally advanced head and neck cancer. NCI Monogr. 1988; (6):353-6.
Score: 0.004
-
An analysis of induction and adjuvant chemotherapy in the multidisciplinary treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol. 1987 Jan; 5(1):10-20.
Score: 0.003
-
Chemotherapy of advanced salivary gland neoplasms. Cancer. 1982 Dec 01; 50(11):2261-4.
Score: 0.003
-
Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer. 1981 May 15; 47(10):2414-21.
Score: 0.002